Cancer
Malignant Anal Neoplasm
CI-CAN-00007989Explore in graph →
Top-level68 active trials1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007989Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT01937780 | Anal Cancer Radiotherapy Study(ANCARAD) | active not recruiting | — | 75 | Oslo University HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) |
| active not recruiting |
| Phase 2 |
| 184 |
| SOLTI Breast Cancer Research GroupOTHER |
| 1 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT05939401 | A Study Regarding Tissue Response During and After Treatment for Anal Cancer(ANCABio) | recruiting | — | 400 | Sahlgrenska University HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06697964 | High Resolution Anuscopy Study | recruiting | — | 500 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06792604 | Host Genome Methylation: a Screening Tool in Anal Cancer Detection(AMethysT) | recruiting | N/A | 770 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06562140 | Multidimensional Examination of Patients with Colorectal and Anal Cancer(MECACP) | unknown | — | 300 | University of PecsOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT03489707 | The Prevent Anal Cancer Self-Swab Study | completed | N/A | 253 | Medical College of WisconsinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05959564 | A Chatbot Intervention for Reducing HPV Vaccine Hesitancy | completed | N/A | 456 | University of Maryland, College ParkOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06619743 | HPV Infection and Vaginal Microecology in Immunosuppressed Women | not yet recruiting | — | 10,000 | Lan ZhuOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT05385250 | Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II(DACG-II) | unknown | N/A | 100 | Karen-Lise Garm SpindlerOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05570279 | PLAN-A Data- Bio- and Plan- Bank Collection for SCCA in Denmark(PLAN-A) | unknown | — | 314 | Aarhus University HospitalOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05572801 | NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer | recruiting | N/A | 400 | Aarhus University HospitalOTHER | 4 | Aug 14, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02135419 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions(ANCHOR) | completed | Phase 3 | 4,446 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 26, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04090060 | The Prevent Anal Cancer Palpation Study | completed | N/A | 718 | Medical College of WisconsinOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06327568 | Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03856437 | A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination | completed | N/A | 1,170 | University of Maryland, College ParkOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05130073 | 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer | completed | — | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04626466 | Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation(MIFADORESOL) | completed | — | 100 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02379039 | Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer(MORRIS) | completed | — | 118 | Umeå UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT02546973 | Quality of Life in Patients With Anal Cancer(ANCA) | unknown | — | 300 | Sahlgrenska University HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT04792892 | ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer(ANCAII) | recruiting | — | 600 | Sahlgrenska University HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT01946139 | Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV | completed | N/A | 276 | AIDS Malignancy ConsortiumNETWORK | 2 | Nov 7, 2023 | clinicaltrials |
| NCT05438836 | Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer(ROAR-A) | recruiting | — | 205 | Herlev HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00316888 | Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer | completed | Phase 2 | 63 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03690921 | Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02919969 | Pembrolizumab in Metastatic Anal Cancer | completed | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT05835947 | Anal Cancer Risk In Women | unknown | — | 200 | Imperial College LondonOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05835960 | Anal Intraepithelial Neoplasia and Anal Squamous Cell Carcinoma | unknown | — | 20 | Imperial College LondonOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT00093379 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT02399813 | A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal | completed | Phase 2 | 36 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2025source: clinicaltrials